Data Update

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Disclaimer · the source of content originated from an external provide and placement with press releases may or may not have been paid-for. Use at your own risk.

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

Globe Newswire - Mon May 23, 5:45AM CDT

NEW YORK and MAINZ, GERMANY, MAY 23, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo.

Symbol	Name

Instrument NameBiontech Se ADRInstrument Symbol(BNTX-Q)Instrument ExchangeNASDAQ

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

Instrument NameBiontech Se ADRInstrument Symbol(BNTX-Q)
Instrument ExchangeNASDAQ